MedPath

IGC Pharma LLC

🇺🇸United States
Ownership
Subsidiary
Employees
-
Market Cap
-
Website
http://igcpharma.com

Clinical Trials

2

Active:0
Completed:1

Trial Phases

2 Phases

Phase 1:1
Phase 2:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (50.0%)
Phase 2
1 (50.0%)

Clinical Trial on Agitation in Alzheimer's Dementia

Phase 2
Recruiting
Conditions
Alzheimer Disease
Agitation,Psychomotor
Care Giving Burden
NPS
Aggression
Interventions
Drug: IGC-AD1-Active
Drug: IGC-AD1-Placebo
First Posted Date
2022-09-16
Last Posted Date
2025-06-12
Lead Sponsor
IGC Pharma, LLC
Target Recruit Count
164
Registration Number
NCT05543681
Locations
🇺🇸

Tekton Research LLC, Yukon, Oklahoma, United States

🇨🇦

Island Health Authorities, Victoria, British Columbia, Canada

🇺🇸

ClinCloud, LLC, Melbourne, Florida, United States

and more 18 locations

Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease

Phase 1
Completed
Conditions
Dementia of Alzheimer Type
Interventions
Drug: Placebo
First Posted Date
2021-02-11
Last Posted Date
2022-09-16
Lead Sponsor
IGC Pharma LLC
Target Recruit Count
12
Registration Number
NCT04749563
Locations
🇵🇷

Puerto Rico, San Juan, Puerto Rico

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.